Literature DB >> 15710216

Hepatitis C virus viral recurrence and liver mitochondrial damage after liver transplantation in HIV-HCV co-infected patients.

Jean-Charles Duclos-Vallée1, Daniel Vittecoq, Elina Teicher, Cyrille Feray, Anne-Marie Roque-Afonso, Anne Lombès, Claude Jardel, Michelle Gigou, Elisabeth Dussaix, Mylène Sebagh, Catherine Guettier, Daniel Azoulay, René Adam, Philippe Ichaï, Faouzi Saliba, Bruno Roche, Denis Castaing, Henri Bismuth, Didier Samuel.   

Abstract

BACKGROUND/AIMS: As life expectancy in HIV-HCV co-infected patients improves, end stage liver disease requiring liver transplantation (LT) may become an emerging problem. We report the Paul Brousse Hospital experience of transplantation for end stage cirrhosis in HIV-HCV co-infected patients.
METHODS: Seven consecutive HIV-HCV co-infected patients were transplanted between December 1999 and December 2002 for end stage liver disease due to HCV. All patients were treated by highly active antiretroviral therapy (HAART), HIV plasma viral load was <400 copies/ml and median CD4 lymphocyte count was 306 cells/mm3 (range, 103-510) before LT. At the time of evaluation (March 2003), the median follow-up was 21 months (range, 4-40).
RESULTS: Two patients died, 4 and 22 months, respectively after LT. At the last biopsy, METAVIR score was staged F4 in two patients, F3 in two, and F1 in one. Microvesicular steatosis was noted in nearly all patients. The ratio of mitochondrial to nuclear DNA was low in three of four patients examined as compared with the amount of liver mtDNA found in eight HIV-negative, HCV-infected controls (P=0.01).
CONCLUSIONS: A significant defect in the activity of the respiratory chain complex IV was noted in all five patients studied. Mitochondrial hepatotoxicity and severe HCV recurrence occur in HIV-HCV co-infected patients after LT.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15710216     DOI: 10.1016/j.jhep.2004.11.029

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  7 in total

1.  Solid organ transplantation and HIV: A changing paradigm.

Authors:  Bl Johnston; Jm Conly
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-11       Impact factor: 2.471

Review 2.  Liver transplantation for patients with human immunodeficiency virus and hepatitis C virus coinfection with special reference to hemophiliac recipients in Japan.

Authors:  Susumu Eguchi; Akihiko Soyama; Masaaki Hidaka; Mitsuhisa Takatsuki; Izumi Muraoka; Tetsuo Tomonaga; Takashi Kanematsu
Journal:  Surg Today       Date:  2011-09-16       Impact factor: 2.549

3.  Liver transplantation in HCV/HIV positive patients.

Authors:  Yasuhiko Sugawara; Sumihito Tamura; Norihiro Kokudo
Journal:  World J Gastrointest Surg       Date:  2011-02-27

4.  Dual inhibition of HCV and HIV by ring-expanded nucleosides containing the 5:7-fused imidazo[4,5-e][1,3]diazepine ring system. In vitro results and implications.

Authors:  Ning Zhang; Peng Zhang; Andrea Baier; Lucyna Cova; Ramachandra S Hosmane
Journal:  Bioorg Med Chem Lett       Date:  2014-01-08       Impact factor: 2.823

Review 5.  Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era.

Authors:  Douglas C MacDonald; Mark Nelson; Mark Bower; Thomas Powles
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

6.  Mitochondrial dysfunction and biogenesis: do ICU patients die from mitochondrial failure?

Authors:  Andrey V Kozlov; Soheyl Bahrami; Enrico Calzia; Peter Dungel; Lars Gille; Andrey V Kuznetsov; Jakob Troppmair
Journal:  Ann Intensive Care       Date:  2011-09-26       Impact factor: 6.925

7.  Living donor domino liver transplantation in a hepatitis C virus/human immunodeficiency virus-coinfected hemophilia patient: a case report.

Authors:  Hidekazu Yamamoto; Yasuhiko Sugawara; Yuzuru Sambommatsu; Keita Shimata; Daiki Yoshii; Kaori Isono; Masaki Honda; Taro Yamashita; Shuzo Matsushita; Yukihiro Inomata; Taizo Hibi
Journal:  Surg Case Rep       Date:  2020-07-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.